Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine

Osher Fellow (University of Arizona Integrative Medicine Fellowship Graduate)  IFM Scholarship Recipient

Direct Integrative Care  |  March 2026

Abstract

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) remains one of the most misunderstood and prematurely diagnosed conditions in modern medicine. While the 2015 Institute of Medicine report established rigorous diagnostic criteria requiring the exclusion of alternative explanations, clinical reality tells a different story. Patients are frequently labeled with ME/CFS after minimal evaluation, leaving treatable conditions—thyroid dysfunction, chronic infections, adrenal imbalance, autoimmune disease, and nutritional deficiencies—unaddressed. This article argues that ME/CFS should function as a diagnosis of exclusion, arrived at only after an exhaustive functional medicine workup. When patients initially respond to therapies such as low-dose naltrexone (LDN) but subsequently plateau, the appropriate clinical response is not simply to adjust the medication—it is to re-examine the underlying diagnosis. Fatigue is a signal, not a disease, and only by systematically pursuing its root cause can clinicians offer patients the comprehensive care they deserve.

Introduction

In integrative and functional medicine, few clinical scenarios are more frustrating than the patient who has been carrying a diagnosis of chronic fatigue syndrome for years, yet has never received a thorough evaluation of why they are fatigued. ME/CFS is a legitimate, serious, and debilitating illness—the 2015 Institute of Medicine report was unequivocal in affirming its medical, rather than psychological, nature (Committee on the Diagnostic Criteria for ME/CFS, 2015). The IOM proposed revised criteria requiring a substantial reduction in pre-illness activity levels persisting for more than six months, accompanied by fatigue that is not the result of ongoing excessive exertion and is not substantially alleviated by rest, along with post-exertional malaise, unrefreshing sleep, and either cognitive impairment or orthostatic intolerance.

However, the very rigor of these criteria carries an implicit expectation: before a clinician assigns the ME/CFS label, other explanatory diagnoses must be carefully considered and excluded. In practice, this step is often skipped. The result is a population of patients who may carry the ME/CFS diagnosis prematurely—patients who, beneath their fatigue, harbor identifiable and treatable conditions that have simply never been investigated.

A Common Clinical Scenario

Consider a scenario encountered regularly in integrative medicine practice. A patient presents with severe, unrelenting fatigue. They have been diagnosed with ME/CFS, often after a brief office visit and limited bloodwork. They are started on low-dose naltrexone (LDN), and for a time, their symptoms improve. LDN has demonstrated promising preliminary evidence in the ME/CFS population—a retrospective analysis of 218 patients found that 73.9% reported a positive treatment response, including improved vigilance, alertness, and cognitive and physical performance (Polo et al., 2019). More recent research has elucidated a plausible mechanism involving restoration of impaired TRPM3 ion channel function in natural killer cells (Cabanas et al., 2021).

But then the improvement stalls. The patient’s fatigue returns, or the initial benefits gradually erode. At this point, the reflexive response in many clinical settings is to adjust the LDN dosage, add another medication, or simply tell the patient that this is the nature of ME/CFS. The more important question is rarely asked: Was the underlying cause of this patient’s fatigue ever fully evaluated?

The Problem with ME/CFS Diagnosis in Clinical Practice

The IOM criteria represent a significant advance in defining ME/CFS. However, the diagnostic process requires something that many clinical encounters fail to provide: a comprehensive exclusionary workup. The IOM committee itself emphasized that “a thorough history, physical examination, and targeted work-up are necessary and often sufficient for diagnosis” (Committee on the Diagnostic Criteria for ME/CFS, 2015). The Medscape differential diagnosis framework for ME/CFS states the principle plainly: once a specific cause of fatigue has been identified, ME/CFS is excluded by definition.

Yet in everyday practice, many patients receive a diagnosis of ME/CFS after minimal testing—perhaps a complete blood count, basic metabolic panel, and thyroid-stimulating hormone (TSH) level. This abbreviated evaluation misses a vast landscape of potential contributing factors. Patients are left with a label but no actionable path forward, and treatable conditions continue to silently erode their quality of life.

The consequences are significant. A premature ME/CFS diagnosis can discourage both the patient and subsequent clinicians from pursuing further investigation. Once the label is in place, it tends to follow the patient through the healthcare system, creating a kind of diagnostic inertia that is difficult to overcome. The patient accepts their fate, and the physician moves on to the next case.

The Functional Medicine Framework for Fatigue

A thorough fatigue evaluation, informed by functional medicine principles and the Institute for Functional Medicine (IFM) matrix model, should systematically address every major physiologic system that can produce or perpetuate fatigue. The following domains deserve careful assessment before ME/CFS is considered as a working diagnosis.

Sleep Assessment

Sleep quality is the foundation upon which energy metabolism rests, and yet it is often the most superficially evaluated domain. Obstructive sleep apnea, upper airway resistance syndrome, and circadian rhythm disruption are remarkably common in fatigued patients and can fully account for symptoms that mimic ME/CFS. A sleep study should be considered in any patient with persistent fatigue, particularly those with snoring, witnessed apneas, morning headaches, or difficulty maintaining a consistent sleep-wake cycle. It is worth noting that Olli Polo, the lead researcher of the Finnish LDN-ME/CFS study, is himself a former professor of respiratory medicine whose ME/CFS research grew directly from his expertise in sleep disorders—a reminder of how deeply intertwined these domains can be.

Hormonal Evaluation

A single TSH level is insufficient to characterize thyroid function. A comprehensive thyroid panel should include free T3, free T4, reverse T3, and thyroid peroxidase and thyroglobulin antibodies. Hashimoto’s thyroiditis can produce fatigue, cognitive impairment, and malaise that perfectly mimic ME/CFS while presenting with a “normal” TSH. Similarly, cortisol patterns—assessed through salivary cortisol testing or a DUTCH (Dried Urine Test for Comprehensive Hormones) panel—can reveal hypothalamic-pituitary-adrenal axis dysfunction that drives fatigue through mechanisms entirely distinct from ME/CFS pathophysiology. Sex hormone imbalances, particularly estrogen and testosterone decline, should also be evaluated, as they frequently contribute to fatigue presentations across both men and women.

Hidden Infections

Chronic infections represent one of the most commonly overlooked drivers of persistent fatigue. Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation can produce low-grade immune activation and fatigue that persists for months or years. Viral titers—including IgG, IgM, and early antigen panels—should be assessed in any patient with unexplained fatigue, particularly those with a history of infectious mononucleosis or other viral illness. Mycoplasma pneumoniae, human herpesvirus 6 (HHV-6), and other chronic intracellular infections deserve consideration as well.

Nutritional Deficiencies

Iron deficiency, even in the absence of frank anemia, can produce profound fatigue. A serum ferritin level below 30–50 ng/mL is increasingly recognized as functionally insufficient, particularly in premenopausal women and individuals with chronic inflammatory states. Vitamin B12, folate, vitamin D, magnesium, and zinc deficiencies are common and easily correctable yet frequently overlooked. These are not esoteric functional medicine tests—they are basic nutritional parameters that should be part of any comprehensive fatigue evaluation.

Endocrine Dysfunction

Beyond thyroid assessment, insulin resistance and metabolic syndrome represent underappreciated drivers of fatigue. Fasting insulin, hemoglobin A1c, and a glucose tolerance test can reveal metabolic dysfunction long before a formal diabetes diagnosis. Adrenal dysfunction—whether frank adrenal insufficiency or the subtler patterns of HPA axis dysregulation—should be evaluated through cortisol testing rather than assumed on clinical grounds alone.

Autoimmune Disease

Autoimmune conditions are among the most commonly missed drivers of chronic fatigue. Systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis, and other autoimmune diseases frequently present with fatigue as a primary or predominant symptom. An antinuclear antibody (ANA) panel, inflammatory markers (ESR, CRP), and targeted autoimmune testing should be considered in any patient with fatigue accompanied by joint pain, rash, dry eyes or mouth, or other systemic symptoms. These conditions are treatable, and their identification can dramatically alter a patient’s trajectory.

Lyme Disease: The Great Pretender in the Fatigue Differential

Lyme disease deserves particular attention in any discussion of ME/CFS because its clinical presentation overlaps substantially with ME/CFS symptomatology, and because its laboratory diagnosis remains profoundly imperfect. The CDC-recommended two-tiered serologic testing algorithm—consisting of an initial enzyme immunoassay followed by Western immunoblot—has a sensitivity of only 30–40% during early infection, and while sensitivity improves to 70–100% in disseminated disease, these figures still leave a significant diagnostic gap (Moore et al., 2016). Immunoblots in particular are technically demanding, subject to reader interpretation variability, and may lack sensitivity in early localized disease (Landry et al., 2024).

The clinical implications are significant. A negative Lyme test does not definitively exclude Lyme disease, particularly in patients with early or partially treated infection. Clinical judgment remains essential, and the integration of exposure history, symptom pattern, and response to empiric treatment may be more informative than serology alone in certain clinical contexts. Furthermore, tick-borne co-infections—including Babesia, Anaplasma, Ehrlichia, and Bartonella—can produce syndromes indistinguishable from ME/CFS and may require specialized testing beyond standard Lyme panels. Research has demonstrated that patients co-infected with Borrelia burgdorferi and Babesia microti experience a greater number and diversity of symptoms and take longer to resolve their illness (Rebman & Aucott, 2020).

For the clinician evaluating persistent fatigue, this means that Lyme disease cannot be excluded on the basis of a negative two-tiered test alone. Advanced testing through specialty laboratories, clinical correlation, and a high index of suspicion in endemic areas are all necessary components of a thorough evaluation. The cost and accessibility barriers to advanced tick-borne disease testing represent a systemic failure that disproportionately affects patients in the very demographic most likely to be dismissed with a premature ME/CFS label.

Why Patients Stay Sick

The reasons patients remain undiagnosed and undertreated are not mysterious—they are structural. Insurance-driven healthcare models incentivize brief encounters and narrow testing panels. Fifteen-minute office visits do not allow for the comprehensive history-taking that complex fatigue cases demand. Laboratory testing is constrained by formularies and prior authorization requirements that may not cover advanced panels for viral reactivation, Lyme co-infections, or comprehensive hormonal assessment. Fragmented care across multiple specialists—none of whom take ownership of the full clinical picture—further compounds the problem.

The result is a system that reliably produces symptomatic management rather than diagnostic clarity. Patients are treated with medications aimed at their symptoms—sleep aids for insomnia, stimulants for fatigue, antidepressants for mood—without ever identifying the physiologic driver of those symptoms. This approach is not only ineffective in the long term; it can be actively harmful, as it delays the identification of treatable conditions and exposes patients to the risks of chronic polypharmacy.

Reframing Fatigue: A Signal, Not a Sentence

The most important conceptual shift in approaching persistent fatigue is this: fatigue is not a disease. It is a signal. It is the body’s way of communicating that something is wrong—that a system is under stress, that a resource is depleted, that a pathologic process is consuming energy that should be available for daily life. To label that signal as ME/CFS without investigating its source is to mistake the alarm for the fire.

Common overlooked causes of persistent fatigue include thyroid dysfunction (particularly subclinical or autoimmune thyroid disease), chronic viral or bacterial infections, immune activation and dysregulation, poor sleep architecture, nutritional insufficiency, hormonal decline, metabolic dysfunction, environmental exposures including mold and biotoxin illness, and mitochondrial dysfunction. Each of these represents a distinct pathophysiologic mechanism with its own diagnostic pathway and therapeutic approach. Grouping them all under the umbrella of ME/CFS serves neither the patient nor the science.

This is not to diminish the reality of true ME/CFS. For patients who have undergone exhaustive evaluation and meet criteria after all other explanations have been carefully excluded, ME/CFS is a legitimate and devastating diagnosis that deserves recognition, research funding, and compassionate care. The argument here is not against the disease—it is against the premature application of the label in the absence of adequate investigation.

Practical Takeaways

For patients and clinicians alike, the message of this article can be distilled to three essential principles. First, ME/CFS should be the last diagnosis considered, not the first. It is a diagnosis of exclusion, and it requires that exclusion to be rigorous and comprehensive. Second, a thorough functional medicine workup—encompassing sleep, hormones, infections, nutrition, endocrine function, autoimmunity, and environmental exposures—is not a luxury or an indulgence. It is a medical necessity for any patient presenting with persistent, unexplained fatigue. Third, when a therapy such as LDN initially helps but then loses effectiveness, this is a clinical signal that warrants renewed investigation of the underlying diagnosis, not merely dose adjustment.

Persistent fatigue always has a driver. Sometimes that driver is ME/CFS. But far more often than current clinical practice acknowledges, it is something else—something treatable, something identifiable, something that requires only the willingness to look more deeply.

Telemedicine Services

At Direct Integrative Care, we offer comprehensive fatigue evaluations through our membership-based telemedicine practice, serving patients across Iowa, Illinois, Missouri, Texas, Georgia, and Florida. Our approach includes advanced laboratory testing encompassing full thyroid panels, viral titers, Lyme and co-infection panels, nutritional assessments, and hormonal evaluations; functional medicine assessments guided by the IFM matrix model; and personalized treatment plans that address root causes rather than merely suppressing symptoms. We believe that every patient with persistent fatigue deserves the thorough evaluation that most healthcare settings cannot provide within the constraints of insurance-driven medicine.

To learn more about our practice and fee schedule, visit www.directintegrativecare.com.

About the Author

Yoon Hang Kim, MD, MPH is a board-certified physician in Preventive Medicine and Integrative & Holistic Medicine, with over 20 years of clinical experience in integrative and functional medicine. He is a Certified Medical Acupuncturist (UCLA), Osher Fellow trained under Dr. Andrew Weil at the University of Arizona, and an Institute for Functional Medicine (IFM) Scholar. Dr. Kim is a recognized expert in low-dose naltrexone (LDN) therapy, having authored multiple books and articles on the subject, and leads the LDN Support Group, a community of over 7,000 members. He has established integrative medicine programs at multiple institutions including Miami Cancer Institute and the University of Kansas Medical Center, and has served in VA, academic, rural community, and direct care settings.

He currently practices at Direct Integrative Care (www.directintegrativecare.com) and Hill Country Integrative Medicine in Fredericksburg, Texas.

Website: yoonhangkim.com    |    LDN Support Group: LDNSupportGroup.com

References

Bolton, M. J., Chapman, B. P., & Van Marwijk, H. (2020). Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Reports, 13(1), e232502. https://doi.org/10.1136/bcr-2019-232502

Cabanas, H., Muraki, K., Eaton-Fitch, N., Staines, D. R., & Marshall-Gradisnik, S. (2021). Potential therapeutic benefit of low dose naltrexone in myalgic encephalomyelitis/chronic fatigue syndrome: Role of transient receptor potential melastatin 3 ion channels in pathophysiology and treatment. Frontiers in Immunology, 12, 687806. https://doi.org/10.3389/fimmu.2021.687806

Centers for Disease Control and Prevention. (2024). IOM 2015 diagnostic criteria: Myalgic encephalomyelitis/chronic fatigue syndrome. https://www.cdc.gov/me-cfs/hcp/diagnosis/iom-2015-diagnostic-criteria-1.html

Centers for Disease Control and Prevention. (2026). Clinical testing and diagnosis for Lyme disease. https://www.cdc.gov/lyme/hcp/diagnosis-testing/index.html

Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Board on the Health of Select Populations; Institute of Medicine. (2015). Beyond myalgic encephalomyelitis/chronic fatigue syndrome: Redefining an illness. National Academies Press. https://doi.org/10.17226/19012

Landry, M. L., Hassan, S., Rottmann, B. G., Pesak, S. J., Ordazzo, M., Skrzyniarz, M., Deponte, S., & Peaper, D. R. (2024). Performance of two modified two-tier algorithms for the serologic diagnosis of Lyme disease. Journal of Clinical Microbiology, 62(5), e00139-24. https://doi.org/10.1128/jcm.00139-24

Moore, A., Nelson, C., Molins, C., Mead, P., & Schriefer, M. (2016). Current guidelines, common clinical pitfalls, and future directions for laboratory diagnosis of Lyme disease, United States. Emerging Infectious Diseases, 22(7), 1169–1177. https://doi.org/10.3201/eid2207.151694

Naik, H., Cooke, E., Boulter, T., Dyer, R., Bone, J. N., Tsai, M., Cristobal, J., McKay, R. J., Song, X., & Nacul, L. (2024). Low-dose naltrexone for post-COVID fatigue syndrome: A study protocol for a double-blind, randomised trial in British Columbia. BMJ Open, 14(5), e085272. https://doi.org/10.1136/bmjopen-2024-085272

Polo, O., Pesonen, P., & Tuominen, E. (2019). Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Fatigue: Biomedicine, Health & Behavior, 7(4), 207–217. https://doi.org/10.1080/21641846.2019.1692770

Rebman, A. W., & Aucott, J. N. (2020). Post-treatment Lyme disease as a model for persistent symptoms in Lyme disease. Frontiers in Medicine, 7, 57. https://doi.org/10.3389/fmed.2020.00057

Toljan, K., & Vrooman, B. (2018). Low-dose naltrexone (LDN)—Review of therapeutic utilization. Medical Sciences, 6(4), 82. https://doi.org/10.3390/medsci6040082

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Fatigue evaluation and treatment decisions should be made in partnership with qualified healthcare providers who understand your individual clinical situation.